<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction

Loading...
Thumbnail Image

Departments

School / College / Institute

Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Ulusoy, Nafia Gökçe

Emirdağ, Safiye

Sözer, Ece

Radwan, Mohamed O.

Aksel, Mehran

Özmen, Ali

Yayli, Nurettin

Karayıldırım, Tamer

Alankuş, Özgen

Tateishi, Hiroshi

Date

Language

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Chronic myelogenous leukemia (CML) is characterized by Philadelphia translocation arising from Bcr-Abl fusion gene, which encodes abnormal oncoprotein showing tyrosine kinase (TK) function. Certain mutations in kinase domain, off-target effects and resistance problems of current TK inhibitors require the discovery of novel Abl TK inhibitors. For this purpose, herein, we synthesized new gypsogenin derivatives (6a-l) and evaluated their anticancer effects towards CML cells along with healthy cell line and different leukemic cells. Among these compounds, compound 6l was found as the most active anti-leukemic agent against K562 CML cells compared to imatinib exerting less cytotoxicity towards PBMCs (healthy). This compound also revealed significant anti -leukemic effects against Jurkat cell line. Besides, compound 6l enhanced apoptosis in CML cells with 52.4 % when compared with imatinib (61.8 %) and inhibited Abl TK significantly with an IC50 value of 13.04 +/- 2.48 mu M in a large panel of kinases accentuating Abl TK-mediated apoptosis of compound 6l in CML cells. Molecular docking outcomes showed that compound 6l formed mainly crucial interactions in the ATP-binding cleft of Abl TK similar to that of imatinib. Ultimately, in silico pharmacokinetic evaluation of compound 6l indicated that this compound was endowed with anti-leukemic drug candidate features.

Source

Publisher

Elsevier

Citation

item.page.haspartof

Source

International Journal of Biological Macromolecules

item.page.ispartofseries

item.page.edition

DOI

10.1016/j.ijbiomac.2022.09.257

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Item type:Goal, Access status: Open Access ,
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.
Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators